Diligence memo · auto-generated · as of July 2, 2026

TOPAS Solutions Inc.

TOPAS Solutions Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

TOPAS Solutions Inc. operates in Biotechnology, based in Providence.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

TOPAS Solutions Inc. has raised $568K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $568K on 2026-03-11.

Most recent recorded round closed around 2026-03-11.

Valuation (modeled)modeled

Provath models TOPAS Solutions Inc. at approximately $917K (range $303K–$1.8M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.96× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era. Within the normal band (96% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 4 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).

Modeled value ranks above 2% of those peers.

Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.